SABCS 2023 | Highlights from SABCS 2024: KEYNOTE-756 and CheckMate 7FL

Virginia Kaklamani, MD, UT Health San Antonio, provides updates on immunotherapy in the early-stage breast cancer setting. She discusses two key clinical trials, the Phase III KEYNOTE-756 (NCT03725059) and CheckMate 7FL (NCT04109066) trials, both focusing on high-risk early-stage breast cancer patients with ER-positive disease and the addition of immunotherapy to the chemotherapy regimen. Although the trials have demonstrated an improvement in pathologic complete response (pCR), event-free survival (EFS) data is yet to be available. Prof. Kaklamani emphasizes the importance of identifying specific subsets of high-risk patients with HR-positive, early-stage breast cancer who would benefit from immunotherapy. This interview took place at the SABCS congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.